公司資料

Genenta Science 股價、新聞與催化劑

股票代碼:
GNTA
交易所:
NASDAQ
產業:
Biopharma
所在地:
Italy and listed in the U

股票表現

1.26 USD (+5.88%)

收盤價

最後更新: 2026年8月21日

51.9M USD

市值

股價為何變動

As of Aug 21, 2026, GNTA closed up 5.88% at $1.26. No new same-company headline was identified in the current news window.

公司概覽

業務概覽

Genenta Science is a cell-therapy company focused on engineered myeloid cells and cancer immunotherapy. Its platform aims to create a new class of cellular medicine for oncology.

所在地與產業分類

Headquartered in Italy and listed in the U.S. as an ADR, Genenta has a global cell-therapy profile.

商業模式特徵

The company depends on platform validation, clinical data, and the ability to turn engineered-cell science into oncology value.

生技產業定位

Genenta is a high-catalyst cell-therapy name whose stock reacts to translational and clinical milestones.

未來催化劑

  • Genenta’s catalysts are its onco-immunology platform and any data that show the hematology / solid-tumor approach can still advance. The company remains early and data-dependent.

近期新聞

  1. 01
  2. 02
  3. 03
  4. 04
  5. 05

相似股票

商業成熟度、治療領域或催化劑模式相近的同業公司。